– This agreement is a milestone for CarryGenes Therapeutics and a strong validation of our unique hSynC platform's value and potential, says Lennart Dreyer, CEO of CarryGenes Therapeutics. For our shareholders and the company's stakeholders, this represents a concrete commercial validation of our technology and business model, which we aim to develop across multiple therapeutic areas. We are now seeking additional collaboration partners.

– Our platform technology can be applied across a very broad field, beyond human health, including in plant breeding and animal diseases. We anticipate significant interest from additional partners.